Poor
Not Aligned
Patient Risk:
Low
Summary
Only the association between OFEV and nintedanib is supported, with the qualification that the label does not expressly call OFEV a brand name. The remaining claims about European exclusivity, patents, marketing authorization, and generic entry are not addressed by the supplied FDA label.
Category Scores
Accurate Statements
Ofev is the brand name for nintedanib.
Section 11 states that OFEV capsules contain nintedanib, supporting the product–active ingredient association. The label does not expressly state that OFEV is a brand name.
The supplied FDA label does not address patents, exclusivity, European marketing authorization, or generic-entry timing.
The provided label section contains no discussion of these subjects.
No contraindications, boxed warnings, dosing, pregnancy, pediatric-safety, or other direct medication-safety issues are addressed in these claims.
The claims concern product identity and intellectual-property or market-entry topics rather than the listed medication-safety subjects.
Unsupported Statements
In Europe, loss of exclusivity for Ofev may refer to patent expiry or regulatory data/market exclusivity.
The supplied label does not discuss European exclusivity, patent expiry, or regulatory data or market exclusivity.
For small-molecule drugs such as nintedanib, generic entry is generally driven mainly by patents and any remaining regulatory protection.
The supplied label does not discuss generic entry, patents, or regulatory protection.
Biologic-type exclusivities generally do not apply to small-molecule drugs such as nintedanib.
The label identifies nintedanib as a kinase inhibitor but does not address biologic or small-molecule exclusivity frameworks.
Ofev's European marketing authorization is centralized.
The supplied FDA label contains no information about European marketing authorization procedures.
Patent rights for Ofev are enforced at the member-state level.
The label does not discuss patent enforcement or jurisdiction.
A country may experience earlier generic entry if key patents lapse there earlier, while other countries may remain protected longer.
The label does not address country-specific patent expiry or generic-entry timing.
Different patent families for nintedanib may expire on different schedules.
The label contains no patent information.
Secondary patents covering formulations, methods, or dosing regimens may extend practical protection for nintedanib.
The label describes the formulation and available strengths but does not discuss patents or market protection.
Generic nintedanib products can typically enter after key protections expire, provided regulatory requirements are met and no blocking patents remain in force in that country.
The label does not discuss generic products, generic-entry requirements, or blocking patents.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims concern exclusivity, patent rights, authorization procedures, and generic-entry timing rather than dosing, contraindications, warnings, interactions, or other direct medication-safety information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most substantive claims are outside the scope of the supplied FDA prescribing information and therefore cannot be supported from the label.
Suggested Improvement
Clearly distinguish the single label-supported product–ingredient association from the European patent, exclusivity, marketing-authorization, and generic-entry claims, and state that those topics cannot be verified from the supplied FDA label.